nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilutamide—CYP2C19—Arformoterol—chronic obstructive pulmonary disease	0.122	0.178	CbGbCtD
Nilutamide—CYP2C19—Formoterol—chronic obstructive pulmonary disease	0.122	0.178	CbGbCtD
Nilutamide—CYP2C8—Montelukast—chronic obstructive pulmonary disease	0.11	0.161	CbGbCtD
Nilutamide—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.101	0.148	CbGbCtD
Nilutamide—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.101	0.148	CbGbCtD
Nilutamide—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.0767	0.112	CbGbCtD
Nilutamide—CYP2C19—Prednisone—chronic obstructive pulmonary disease	0.0511	0.0748	CbGbCtD
Nilutamide—POR—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.00325	0.0544	CbGpPWpGaD
Nilutamide—Flutamide—CYP1A1—chronic obstructive pulmonary disease	0.00322	0.404	CrCbGaD
Nilutamide—Flutamide—CYP1A2—chronic obstructive pulmonary disease	0.00311	0.39	CrCbGaD
Nilutamide—AR—FOXA1 transcription factor network—SCGB1A1—chronic obstructive pulmonary disease	0.00302	0.0505	CbGpPWpGaD
Nilutamide—POR—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.00236	0.0396	CbGpPWpGaD
Nilutamide—AR—FOXA1 transcription factor network—SFTPD—chronic obstructive pulmonary disease	0.00229	0.0383	CbGpPWpGaD
Nilutamide—CYP2C8—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A2—chronic obstructive pulmonary disease	0.00174	0.0291	CbGpPWpGaD
Nilutamide—Enzalutamide—ALB—chronic obstructive pulmonary disease	0.00164	0.206	CrCbGaD
Nilutamide—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—chronic obstructive pulmonary disease	0.00161	0.027	CbGpPWpGaD
Nilutamide—CYP2C8—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A2—chronic obstructive pulmonary disease	0.00158	0.0265	CbGpPWpGaD
Nilutamide—CYP2C19—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A2—chronic obstructive pulmonary disease	0.00155	0.026	CbGpPWpGaD
Nilutamide—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A2—chronic obstructive pulmonary disease	0.00141	0.0237	CbGpPWpGaD
Nilutamide—CYP2C19—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A2—chronic obstructive pulmonary disease	0.00141	0.0236	CbGpPWpGaD
Nilutamide—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—chronic obstructive pulmonary disease	0.00131	0.022	CbGpPWpGaD
Nilutamide—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A2—chronic obstructive pulmonary disease	0.00129	0.0216	CbGpPWpGaD
Nilutamide—CYP2C8—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—chronic obstructive pulmonary disease	0.00126	0.0211	CbGpPWpGaD
Nilutamide—AR—FOXA1 transcription factor network—SERPINA1—chronic obstructive pulmonary disease	0.00123	0.0207	CbGpPWpGaD
Nilutamide—CYP2C8—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—chronic obstructive pulmonary disease	0.00115	0.0192	CbGpPWpGaD
Nilutamide—CYP2C19—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—chronic obstructive pulmonary disease	0.00113	0.0189	CbGpPWpGaD
Nilutamide—Upper respiratory tract infection—Salbutamol—chronic obstructive pulmonary disease	0.00104	0.00419	CcSEcCtD
Nilutamide—Urinary tract infection—Arformoterol—chronic obstructive pulmonary disease	0.00103	0.00414	CcSEcCtD
Nilutamide—Urinary tract infection—Formoterol—chronic obstructive pulmonary disease	0.00103	0.00414	CcSEcCtD
Nilutamide—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—chronic obstructive pulmonary disease	0.00103	0.0172	CbGpPWpGaD
Nilutamide—CYP2C19—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—chronic obstructive pulmonary disease	0.00103	0.0172	CbGpPWpGaD
Nilutamide—Hyperglycaemia—Salbutamol—chronic obstructive pulmonary disease	0.00101	0.00407	CcSEcCtD
Nilutamide—Haematuria—Arformoterol—chronic obstructive pulmonary disease	0.00101	0.00406	CcSEcCtD
Nilutamide—Haematuria—Formoterol—chronic obstructive pulmonary disease	0.00101	0.00406	CcSEcCtD
Nilutamide—Back pain—Tiotropium—chronic obstructive pulmonary disease	0.000993	0.00399	CcSEcCtD
Nilutamide—Urinary tract infection—Salbutamol—chronic obstructive pulmonary disease	0.000973	0.00391	CcSEcCtD
Nilutamide—Sweating—Salbutamol—chronic obstructive pulmonary disease	0.000959	0.00385	CcSEcCtD
Nilutamide—Asthenia—Roflumilast—chronic obstructive pulmonary disease	0.000956	0.00384	CcSEcCtD
Nilutamide—Haematuria—Salbutamol—chronic obstructive pulmonary disease	0.000954	0.00383	CcSEcCtD
Nilutamide—Rhinitis—Formoterol—chronic obstructive pulmonary disease	0.000954	0.00383	CcSEcCtD
Nilutamide—Rhinitis—Arformoterol—chronic obstructive pulmonary disease	0.000954	0.00383	CcSEcCtD
Nilutamide—Urinary tract disorder—Arformoterol—chronic obstructive pulmonary disease	0.00094	0.00377	CcSEcCtD
Nilutamide—Urinary tract disorder—Formoterol—chronic obstructive pulmonary disease	0.00094	0.00377	CcSEcCtD
Nilutamide—Oedema peripheral—Formoterol—chronic obstructive pulmonary disease	0.000937	0.00377	CcSEcCtD
Nilutamide—Oedema peripheral—Arformoterol—chronic obstructive pulmonary disease	0.000937	0.00377	CcSEcCtD
Nilutamide—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—chronic obstructive pulmonary disease	0.000935	0.0157	CbGpPWpGaD
Nilutamide—Rhinitis—Montelukast—chronic obstructive pulmonary disease	0.000934	0.00375	CcSEcCtD
Nilutamide—Urethral disorder—Arformoterol—chronic obstructive pulmonary disease	0.000933	0.00375	CcSEcCtD
Nilutamide—Urethral disorder—Formoterol—chronic obstructive pulmonary disease	0.000933	0.00375	CcSEcCtD
Nilutamide—Hypoaesthesia—Montelukast—chronic obstructive pulmonary disease	0.000927	0.00373	CcSEcCtD
Nilutamide—Syncope—Tiotropium—chronic obstructive pulmonary disease	0.00092	0.0037	CcSEcCtD
Nilutamide—Urinary tract disorder—Montelukast—chronic obstructive pulmonary disease	0.00092	0.0037	CcSEcCtD
Nilutamide—Visual impairment—Arformoterol—chronic obstructive pulmonary disease	0.000917	0.00368	CcSEcCtD
Nilutamide—Visual impairment—Formoterol—chronic obstructive pulmonary disease	0.000917	0.00368	CcSEcCtD
Nilutamide—Urethral disorder—Montelukast—chronic obstructive pulmonary disease	0.000913	0.00367	CcSEcCtD
Nilutamide—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.000911	0.00366	CcSEcCtD
Nilutamide—Loss of consciousness—Tiotropium—chronic obstructive pulmonary disease	0.000902	0.00362	CcSEcCtD
Nilutamide—Rhinitis—Salbutamol—chronic obstructive pulmonary disease	0.000901	0.00362	CcSEcCtD
Nilutamide—Cough—Tiotropium—chronic obstructive pulmonary disease	0.000896	0.0036	CcSEcCtD
Nilutamide—Hypoaesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000894	0.00359	CcSEcCtD
Nilutamide—Urinary tract disorder—Salbutamol—chronic obstructive pulmonary disease	0.000887	0.00356	CcSEcCtD
Nilutamide—Hypertension—Tiotropium—chronic obstructive pulmonary disease	0.000886	0.00356	CcSEcCtD
Nilutamide—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.000881	0.00354	CcSEcCtD
Nilutamide—Urethral disorder—Salbutamol—chronic obstructive pulmonary disease	0.000881	0.00354	CcSEcCtD
Nilutamide—Shock—Aminophylline—chronic obstructive pulmonary disease	0.000874	0.00351	CcSEcCtD
Nilutamide—Chest pain—Tiotropium—chronic obstructive pulmonary disease	0.000874	0.00351	CcSEcCtD
Nilutamide—Dry mouth—Tiotropium—chronic obstructive pulmonary disease	0.000854	0.00343	CcSEcCtD
Nilutamide—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.000847	0.0034	CcSEcCtD
Nilutamide—Anorexia—Aminophylline—chronic obstructive pulmonary disease	0.000847	0.0034	CcSEcCtD
Nilutamide—Rash—Roflumilast—chronic obstructive pulmonary disease	0.00084	0.00337	CcSEcCtD
Nilutamide—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.000839	0.00337	CcSEcCtD
Nilutamide—Oedema—Tiotropium—chronic obstructive pulmonary disease	0.000838	0.00336	CcSEcCtD
Nilutamide—CYP2C8—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000835	0.014	CbGpPWpGaD
Nilutamide—Headache—Roflumilast—chronic obstructive pulmonary disease	0.000834	0.00335	CcSEcCtD
Nilutamide—Shock—Tiotropium—chronic obstructive pulmonary disease	0.000824	0.00331	CcSEcCtD
Nilutamide—Tension—Formoterol—chronic obstructive pulmonary disease	0.000813	0.00327	CcSEcCtD
Nilutamide—Tension—Arformoterol—chronic obstructive pulmonary disease	0.000813	0.00327	CcSEcCtD
Nilutamide—Nervousness—Arformoterol—chronic obstructive pulmonary disease	0.000804	0.00323	CcSEcCtD
Nilutamide—Nervousness—Formoterol—chronic obstructive pulmonary disease	0.000804	0.00323	CcSEcCtD
Nilutamide—Insomnia—Aminophylline—chronic obstructive pulmonary disease	0.000803	0.00323	CcSEcCtD
Nilutamide—CYP2C8—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000803	0.0134	CbGpPWpGaD
Nilutamide—Back pain—Formoterol—chronic obstructive pulmonary disease	0.000801	0.00322	CcSEcCtD
Nilutamide—Back pain—Arformoterol—chronic obstructive pulmonary disease	0.000801	0.00322	CcSEcCtD
Nilutamide—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000791	0.00318	CcSEcCtD
Nilutamide—Visual disturbance—Prednisolone—chronic obstructive pulmonary disease	0.000786	0.00316	CcSEcCtD
Nilutamide—Cataract—Prednisone—chronic obstructive pulmonary disease	0.000783	0.00315	CcSEcCtD
Nilutamide—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.000782	0.00314	CcSEcCtD
Nilutamide—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.000772	0.0031	CcSEcCtD
Nilutamide—Ill-defined disorder—Formoterol—chronic obstructive pulmonary disease	0.000768	0.00309	CcSEcCtD
Nilutamide—Ill-defined disorder—Arformoterol—chronic obstructive pulmonary disease	0.000768	0.00309	CcSEcCtD
Nilutamide—Tension—Salbutamol—chronic obstructive pulmonary disease	0.000767	0.00308	CcSEcCtD
Nilutamide—Nervousness—Salbutamol—chronic obstructive pulmonary disease	0.00076	0.00305	CcSEcCtD
Nilutamide—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.000758	0.00304	CcSEcCtD
Nilutamide—Back pain—Salbutamol—chronic obstructive pulmonary disease	0.000756	0.00304	CcSEcCtD
Nilutamide—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	0.000752	0.00302	CcSEcCtD
Nilutamide—Malaise—Formoterol—chronic obstructive pulmonary disease	0.000747	0.003	CcSEcCtD
Nilutamide—Malaise—Arformoterol—chronic obstructive pulmonary disease	0.000747	0.003	CcSEcCtD
Nilutamide—CYP2C19—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000745	0.0125	CbGpPWpGaD
Nilutamide—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000737	0.00296	CcSEcCtD
Nilutamide—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000726	0.00292	CcSEcCtD
Nilutamide—Ill-defined disorder—Salbutamol—chronic obstructive pulmonary disease	0.000726	0.00292	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000723	0.0029	CcSEcCtD
Nilutamide—Cough—Arformoterol—chronic obstructive pulmonary disease	0.000723	0.0029	CcSEcCtD
Nilutamide—Cough—Formoterol—chronic obstructive pulmonary disease	0.000723	0.0029	CcSEcCtD
Nilutamide—CYP2C19—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000716	0.012	CbGpPWpGaD
Nilutamide—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000716	0.00288	CcSEcCtD
Nilutamide—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.000715	0.00287	CcSEcCtD
Nilutamide—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.000715	0.00287	CcSEcCtD
Nilutamide—Cough—Montelukast—chronic obstructive pulmonary disease	0.000708	0.00284	CcSEcCtD
Nilutamide—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.000705	0.00283	CcSEcCtD
Nilutamide—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.000705	0.00283	CcSEcCtD
Nilutamide—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.000705	0.00283	CcSEcCtD
Nilutamide—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000702	0.00282	CcSEcCtD
Nilutamide—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000702	0.00282	CcSEcCtD
Nilutamide—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000701	0.00282	CcSEcCtD
Nilutamide—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000697	0.0028	CcSEcCtD
Nilutamide—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.000697	0.0028	CcSEcCtD
Nilutamide—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.00069	0.00277	CcSEcCtD
Nilutamide—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.00069	0.00277	CcSEcCtD
Nilutamide—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000687	0.00276	CcSEcCtD
Nilutamide—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000685	0.00275	CcSEcCtD
Nilutamide—Dry skin—Prednisolone—chronic obstructive pulmonary disease	0.000683	0.00274	CcSEcCtD
Nilutamide—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000682	0.00274	CcSEcCtD
Nilutamide—CYP2C9—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000679	0.0114	CbGpPWpGaD
Nilutamide—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000676	0.00272	CcSEcCtD
Nilutamide—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000676	0.00272	CcSEcCtD
Nilutamide—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000675	0.00271	CcSEcCtD
Nilutamide—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000666	0.00267	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—RAPGEF3—chronic obstructive pulmonary disease	0.000664	0.0111	CbGpPWpGaD
Nilutamide—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000662	0.00266	CcSEcCtD
Nilutamide—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000662	0.00266	CcSEcCtD
Nilutamide—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000658	0.00264	CcSEcCtD
Nilutamide—CYP2C9—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000653	0.0109	CbGpPWpGaD
Nilutamide—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000651	0.00262	CcSEcCtD
Nilutamide—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000638	0.00256	CcSEcCtD
Nilutamide—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000628	0.00252	CcSEcCtD
Nilutamide—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000628	0.00252	CcSEcCtD
Nilutamide—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000617	0.00248	CcSEcCtD
Nilutamide—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000611	0.00246	CcSEcCtD
Nilutamide—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000611	0.00246	CcSEcCtD
Nilutamide—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000608	0.00244	CcSEcCtD
Nilutamide—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000608	0.00244	CcSEcCtD
Nilutamide—CYP2C8—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000606	0.0102	CbGpPWpGaD
Nilutamide—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000603	0.00242	CcSEcCtD
Nilutamide—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000603	0.00242	CcSEcCtD
Nilutamide—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000599	0.00241	CcSEcCtD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—HDAC2—chronic obstructive pulmonary disease	0.000595	0.00997	CbGpPWpGaD
Nilutamide—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000595	0.00239	CcSEcCtD
Nilutamide—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000595	0.00239	CcSEcCtD
Nilutamide—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000594	0.00239	CcSEcCtD
Nilutamide—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000593	0.00238	CcSEcCtD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—HDAC2—chronic obstructive pulmonary disease	0.000589	0.00987	CbGpPWpGaD
Nilutamide—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000587	0.00236	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000584	0.00234	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000584	0.00234	CcSEcCtD
Nilutamide—CYP2C8—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000583	0.00977	CbGpPWpGaD
Nilutamide—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000583	0.00234	CcSEcCtD
Nilutamide—Pain—Formoterol—chronic obstructive pulmonary disease	0.000578	0.00232	CcSEcCtD
Nilutamide—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000578	0.00232	CcSEcCtD
Nilutamide—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000578	0.00232	CcSEcCtD
Nilutamide—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000578	0.00232	CcSEcCtD
Nilutamide—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000577	0.00232	CcSEcCtD
Nilutamide—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000573	0.0023	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000572	0.0023	CcSEcCtD
Nilutamide—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000569	0.00229	CcSEcCtD
Nilutamide—Pain—Montelukast—chronic obstructive pulmonary disease	0.000566	0.00227	CcSEcCtD
Nilutamide—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000565	0.00227	CcSEcCtD
Nilutamide—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000562	0.00226	CcSEcCtD
Nilutamide—Rash—Aminophylline—chronic obstructive pulmonary disease	0.00056	0.00225	CcSEcCtD
Nilutamide—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000559	0.00225	CcSEcCtD
Nilutamide—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000557	0.00224	CcSEcCtD
Nilutamide—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000557	0.00224	CcSEcCtD
Nilutamide—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000556	0.00224	CcSEcCtD
Nilutamide—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000555	0.00223	CcSEcCtD
Nilutamide—Cardiac failure—Prednisone—chronic obstructive pulmonary disease	0.000555	0.00223	CcSEcCtD
Nilutamide—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000554	0.00223	CcSEcCtD
Nilutamide—CYP2C19—Melatonin metabolism and effects—CYP1A2—chronic obstructive pulmonary disease	0.000553	0.00927	CbGpPWpGaD
Nilutamide—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000553	0.00222	CcSEcCtD
Nilutamide—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000553	0.00222	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000551	0.00221	CcSEcCtD
Nilutamide—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000546	0.00219	CcSEcCtD
Nilutamide—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000546	0.00219	CcSEcCtD
Nilutamide—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000541	0.00217	CcSEcCtD
Nilutamide—Gastrointestinal haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000541	0.00217	CcSEcCtD
Nilutamide—CYP2C19—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000541	0.00907	CbGpPWpGaD
Nilutamide—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000534	0.00215	CcSEcCtD
Nilutamide—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000534	0.00215	CcSEcCtD
Nilutamide—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000534	0.00215	CcSEcCtD
Nilutamide—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000534	0.00215	CcSEcCtD
Nilutamide—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000533	0.00214	CcSEcCtD
Nilutamide—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000528	0.00212	CcSEcCtD
Nilutamide—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000528	0.00212	CcSEcCtD
Nilutamide—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000528	0.00212	CcSEcCtD
Nilutamide—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000526	0.00211	CcSEcCtD
Nilutamide—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000525	0.00211	CcSEcCtD
Nilutamide—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000523	0.0021	CcSEcCtD
Nilutamide—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000523	0.0021	CcSEcCtD
Nilutamide—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000522	0.0021	CcSEcCtD
Nilutamide—CYP2C19—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.00052	0.00872	CbGpPWpGaD
Nilutamide—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000505	0.00203	CcSEcCtD
Nilutamide—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000505	0.00203	CcSEcCtD
Nilutamide—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000497	0.002	CcSEcCtD
Nilutamide—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.000497	0.00199	CcSEcCtD
Nilutamide—Dry skin—Prednisone—chronic obstructive pulmonary disease	0.000496	0.00199	CcSEcCtD
Nilutamide—CYP2C9—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000493	0.00827	CbGpPWpGaD
Nilutamide—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000485	0.00195	CcSEcCtD
Nilutamide—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000485	0.00195	CcSEcCtD
Nilutamide—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000478	0.00192	CcSEcCtD
Nilutamide—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000478	0.00192	CcSEcCtD
Nilutamide—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000477	0.00192	CcSEcCtD
Nilutamide—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000475	0.00191	CcSEcCtD
Nilutamide—CYP2C9—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000475	0.00795	CbGpPWpGaD
Nilutamide—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000468	0.00188	CcSEcCtD
Nilutamide—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000462	0.00186	CcSEcCtD
Nilutamide—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000462	0.00186	CcSEcCtD
Nilutamide—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000458	0.00184	CcSEcCtD
Nilutamide—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000453	0.00182	CcSEcCtD
Nilutamide—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000452	0.00181	CcSEcCtD
Nilutamide—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000447	0.0018	CcSEcCtD
Nilutamide—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000447	0.0018	CcSEcCtD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—IL10—chronic obstructive pulmonary disease	0.000447	0.00748	CbGpPWpGaD
Nilutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000444	0.00744	CbGpPWpGaD
Nilutamide—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000438	0.00176	CcSEcCtD
Nilutamide—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000437	0.00175	CcSEcCtD
Nilutamide—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.000431	0.00173	CcSEcCtD
Nilutamide—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.00043	0.00173	CcSEcCtD
Nilutamide—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.00043	0.00173	CcSEcCtD
Nilutamide—CYP2C19—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.000429	0.00719	CbGpPWpGaD
Nilutamide—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000426	0.00171	CcSEcCtD
Nilutamide—Rash—Formoterol—chronic obstructive pulmonary disease	0.000426	0.00171	CcSEcCtD
Nilutamide—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000426	0.00171	CcSEcCtD
Nilutamide—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000426	0.00171	CcSEcCtD
Nilutamide—Headache—Formoterol—chronic obstructive pulmonary disease	0.000423	0.0017	CcSEcCtD
Nilutamide—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000423	0.0017	CcSEcCtD
Nilutamide—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000423	0.0017	CcSEcCtD
Nilutamide—AR—SIDS Susceptibility Pathways—IL13—chronic obstructive pulmonary disease	0.000423	0.00708	CbGpPWpGaD
Nilutamide—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000422	0.0017	CcSEcCtD
Nilutamide—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000422	0.0017	CcSEcCtD
Nilutamide—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000421	0.00169	CcSEcCtD
Nilutamide—Rash—Montelukast—chronic obstructive pulmonary disease	0.000417	0.00168	CcSEcCtD
Nilutamide—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000417	0.00168	CcSEcCtD
Nilutamide—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000416	0.00167	CcSEcCtD
Nilutamide—Depression—Prednisone—chronic obstructive pulmonary disease	0.000416	0.00167	CcSEcCtD
Nilutamide—Headache—Montelukast—chronic obstructive pulmonary disease	0.000415	0.00167	CcSEcCtD
Nilutamide—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000406	0.00163	CcSEcCtD
Nilutamide—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000404	0.00162	CcSEcCtD
Nilutamide—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000402	0.00162	CcSEcCtD
Nilutamide—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000402	0.00162	CcSEcCtD
Nilutamide—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000402	0.00162	CcSEcCtD
Nilutamide—CYP2C19—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.000402	0.00674	CbGpPWpGaD
Nilutamide—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000401	0.00161	CcSEcCtD
Nilutamide—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000401	0.00161	CcSEcCtD
Nilutamide—CYP2C8—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000401	0.00672	CbGpPWpGaD
Nilutamide—Headache—Salbutamol—chronic obstructive pulmonary disease	0.0004	0.00161	CcSEcCtD
Nilutamide—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000394	0.00158	CcSEcCtD
Nilutamide—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000393	0.00158	CcSEcCtD
Nilutamide—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000387	0.00156	CcSEcCtD
Nilutamide—AR—SIDS Susceptibility Pathways—SLC6A4—chronic obstructive pulmonary disease	0.000381	0.00639	CbGpPWpGaD
Nilutamide—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000379	0.00152	CcSEcCtD
Nilutamide—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000377	0.00152	CcSEcCtD
Nilutamide—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000366	0.00147	CcSEcCtD
Nilutamide—Shock—Prednisolone—chronic obstructive pulmonary disease	0.00036	0.00145	CcSEcCtD
Nilutamide—CYP2C19—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000358	0.006	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000354	0.00594	CbGpPWpGaD
Nilutamide—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000354	0.00142	CcSEcCtD
Nilutamide—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000347	0.00581	CbGpPWpGaD
Nilutamide—CYP2C8—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000342	0.00573	CbGpPWpGaD
Nilutamide—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000331	0.00133	CcSEcCtD
Nilutamide—Alopecia—Prednisone—chronic obstructive pulmonary disease	0.000331	0.00133	CcSEcCtD
Nilutamide—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000329	0.00132	CcSEcCtD
Nilutamide—CYP2C9—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000326	0.00547	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000316	0.0053	CbGpPWpGaD
Nilutamide—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000313	0.00126	CcSEcCtD
Nilutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000309	0.00518	CbGpPWpGaD
Nilutamide—CYP2C19—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000305	0.00511	CbGpPWpGaD
Nilutamide—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.000302	0.00121	CcSEcCtD
Nilutamide—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000302	0.00121	CcSEcCtD
Nilutamide—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.000301	0.00121	CcSEcCtD
Nilutamide—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000294	0.00118	CcSEcCtD
Nilutamide—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000292	0.00117	CcSEcCtD
Nilutamide—CYP2C8—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000291	0.00488	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000288	0.00483	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—SERPINE1—chronic obstructive pulmonary disease	0.000288	0.00483	CbGpPWpGaD
Nilutamide—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000286	0.00115	CcSEcCtD
Nilutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000282	0.00472	CbGpPWpGaD
Nilutamide—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000281	0.00113	CcSEcCtD
Nilutamide—CYP2C8—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000281	0.00471	CbGpPWpGaD
Nilutamide—CYP2C9—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000278	0.00466	CbGpPWpGaD
Nilutamide—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000274	0.0011	CcSEcCtD
Nilutamide—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000266	0.00107	CcSEcCtD
Nilutamide—AR—SIDS Susceptibility Pathways—IL10—chronic obstructive pulmonary disease	0.000264	0.00443	CbGpPWpGaD
Nilutamide—Shock—Prednisone—chronic obstructive pulmonary disease	0.000262	0.00105	CcSEcCtD
Nilutamide—CYP2C19—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.00026	0.00436	CbGpPWpGaD
Nilutamide—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000257	0.00103	CcSEcCtD
Nilutamide—Anorexia—Prednisone—chronic obstructive pulmonary disease	0.000254	0.00102	CcSEcCtD
Nilutamide—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000252	0.00422	CbGpPWpGaD
Nilutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000251	0.0042	CbGpPWpGaD
Nilutamide—CYP2C8—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000248	0.00416	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—chronic obstructive pulmonary disease	0.000247	0.00413	CbGpPWpGaD
Nilutamide—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000242	0.000973	CcSEcCtD
Nilutamide—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000241	0.000967	CcSEcCtD
Nilutamide—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	0.000239	0.00096	CcSEcCtD
Nilutamide—CYP2C9—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000237	0.00397	CbGpPWpGaD
Nilutamide—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000234	0.000941	CcSEcCtD
Nilutamide—AR—SIDS Susceptibility Pathways—HTR2A—chronic obstructive pulmonary disease	0.000234	0.00392	CbGpPWpGaD
Nilutamide—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000231	0.000929	CcSEcCtD
Nilutamide—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000231	0.000927	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—MMP1—chronic obstructive pulmonary disease	0.000231	0.00386	CbGpPWpGaD
Nilutamide—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000231	0.000926	CcSEcCtD
Nilutamide—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000229	0.000921	CcSEcCtD
Nilutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000229	0.00383	CbGpPWpGaD
Nilutamide—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000227	0.000914	CcSEcCtD
Nilutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000225	0.00376	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—chronic obstructive pulmonary disease	0.000223	0.00374	CbGpPWpGaD
Nilutamide—CYP2C19—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000222	0.00372	CbGpPWpGaD
Nilutamide—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.000219	0.000881	CcSEcCtD
Nilutamide—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000218	0.000874	CcSEcCtD
Nilutamide—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000217	0.000874	CcSEcCtD
Nilutamide—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.00021	0.000845	CcSEcCtD
Nilutamide—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.00021	0.000845	CcSEcCtD
Nilutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000205	0.00343	CbGpPWpGaD
Nilutamide—CYP2C8—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000204	0.00342	CbGpPWpGaD
Nilutamide—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000202	0.00339	CbGpPWpGaD
Nilutamide—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000191	0.000767	CcSEcCtD
Nilutamide—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000188	0.000756	CcSEcCtD
Nilutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000182	0.00305	CbGpPWpGaD
Nilutamide—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000182	0.000731	CcSEcCtD
Nilutamide—CYP2C8—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.00018	0.00301	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000177	0.00297	CbGpPWpGaD
Nilutamide—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000176	0.000707	CcSEcCtD
Nilutamide—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000169	0.000679	CcSEcCtD
Nilutamide—Rash—Prednisone—chronic obstructive pulmonary disease	0.000168	0.000674	CcSEcCtD
Nilutamide—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000168	0.000673	CcSEcCtD
Nilutamide—Headache—Prednisone—chronic obstructive pulmonary disease	0.000167	0.000669	CcSEcCtD
Nilutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000166	0.00278	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—EGFR—chronic obstructive pulmonary disease	0.000166	0.00277	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.00016	0.00268	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000158	0.00265	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—CTGF—chronic obstructive pulmonary disease	0.000158	0.00265	CbGpPWpGaD
Nilutamide—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000158	0.000635	CcSEcCtD
Nilutamide—CYP2C8—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000149	0.0025	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.000147	0.00247	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000146	0.00245	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	0.000145	0.00242	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000144	0.00242	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	0.000139	0.00232	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000133	0.00223	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.000131	0.0022	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	0.000126	0.00211	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000124	0.00208	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	0.000123	0.00206	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000121	0.00203	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	0.00012	0.00202	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.00012	0.00201	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	0.000117	0.00197	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000114	0.00192	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	0.000113	0.00189	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	0.000113	0.00189	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000111	0.00186	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	0.00011	0.00184	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—EGFR—chronic obstructive pulmonary disease	0.000108	0.00182	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000108	0.00182	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	0.000107	0.00179	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	0.000103	0.00172	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000102	0.00171	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000101	0.0017	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	0.000101	0.00169	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	0.000101	0.00169	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	9.99e-05	0.00167	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	9.98e-05	0.00167	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	9.68e-05	0.00162	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	9.54e-05	0.0016	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	9.31e-05	0.00156	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	9.18e-05	0.00154	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	9.16e-05	0.00154	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—TP53—chronic obstructive pulmonary disease	9.1e-05	0.00153	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	8.98e-05	0.00151	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	8.82e-05	0.00148	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—APIP—chronic obstructive pulmonary disease	8.72e-05	0.00146	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	8.7e-05	0.00146	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	8.56e-05	0.00143	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	8.12e-05	0.00136	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—APIP—chronic obstructive pulmonary disease	7.79e-05	0.0013	CbGpPWpGaD
Nilutamide—AR—Gene Expression—CTGF—chronic obstructive pulmonary disease	7.61e-05	0.00128	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	7.54e-05	0.00126	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—SERPINE1—chronic obstructive pulmonary disease	7.21e-05	0.00121	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—APIP—chronic obstructive pulmonary disease	7.1e-05	0.00119	CbGpPWpGaD
Nilutamide—AR—Gene Expression—HDAC2—chronic obstructive pulmonary disease	7.09e-05	0.00119	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	6.22e-05	0.00104	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	5.78e-05	0.000968	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	5.73e-05	0.00096	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GC—chronic obstructive pulmonary disease	5.62e-05	0.000942	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	5.55e-05	0.00093	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	5.23e-05	0.000875	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	5.16e-05	0.000864	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	5.11e-05	0.000857	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	5.06e-05	0.000848	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GC—chronic obstructive pulmonary disease	5.02e-05	0.00084	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	4.7e-05	0.000788	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	4.66e-05	0.000781	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	4.66e-05	0.000781	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	4.57e-05	0.000766	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	4.25e-05	0.000712	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	4.16e-05	0.000697	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	3.72e-05	0.000623	CbGpPWpGaD
Nilutamide—AR—Gene Expression—SERPINE1—chronic obstructive pulmonary disease	3.47e-05	0.000582	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	3.39e-05	0.000568	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.07e-05	0.000514	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GCLC—chronic obstructive pulmonary disease	3.04e-05	0.000508	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	2.83e-05	0.000474	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CTGF—chronic obstructive pulmonary disease	2.77e-05	0.000464	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.74e-05	0.000459	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GCLC—chronic obstructive pulmonary disease	2.71e-05	0.000454	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.55e-05	0.000428	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	2.53e-05	0.000423	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.5e-05	0.000419	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CTGF—chronic obstructive pulmonary disease	2.47e-05	0.000414	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	2.47e-05	0.000414	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	2.3e-05	0.000386	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.28e-05	0.000382	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	2.25e-05	0.000378	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.13e-05	0.000357	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.1e-05	0.000352	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.08e-05	0.000348	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.96e-05	0.000328	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.9e-05	0.000318	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.87e-05	0.000314	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.85e-05	0.000311	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.75e-05	0.000292	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.73e-05	0.00029	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.71e-05	0.000286	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.66e-05	0.000277	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.59e-05	0.000267	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.51e-05	0.000253	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—ALB—chronic obstructive pulmonary disease	1.26e-05	0.000211	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—NOS3—chronic obstructive pulmonary disease	1.21e-05	0.000202	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—ALB—chronic obstructive pulmonary disease	1.12e-05	0.000188	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—NOS3—chronic obstructive pulmonary disease	1.08e-05	0.00018	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	1.03e-05	0.000172	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	9.81e-06	0.000164	CbGpPWpGaD
